Frontier Biotechnologies is responsible for reaching market with the first new HIV medicine discovered and developed in China.
The Chinese company has received marketing authorization from the China Food and Drug Administration for Aikening (albuvirtide for injection, ABT) for the treatment of HIV-1.
ABT is a new chemical entity with a novel molecular mechanism of action and long-acting activity against HIV-1. It has been approved for use in treatment-experienced adults who still have virus replication, in combination with other antiretroviral agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze